Johnson & Johnson (NYSE:JNJ) Shares Unloaded Rep. Robert Bresnahan, Jr.

Representative Robert Bresnahan, Jr. (R-Pennsylvania) recently sold shares of Johnson & Johnson NYSE: JNJ. In a filing disclosed on April 28th, the Representative disclosed that they had sold between $1,001 and $15,000 in Johnson & Johnson stock on April 8th. The trade occurred in the Representative's "JP MORGAN BROKERAGE ACCOUNT" account.

Representative Robert Bresnahan, Jr. also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of DexCom NASDAQ: DXCM on 4/8/2025.
• Sold $1,001 - $15,000 in shares of Invesco NYSE: IVZ on 4/8/2025.
• Sold $1,001 - $15,000 in shares of Generac NYSE: GNRC on 4/8/2025.
• Sold $15,001 - $50,000 in shares of Occidental Petroleum NYSE: OXY on 4/8/2025.
• Sold $15,001 - $50,000 in shares of Pfizer NYSE: PFE on 4/8/2025.
• Sold $1,001 - $15,000 in shares of QUALCOMM NASDAQ: QCOM on 4/8/2025.
• Sold $1,001 - $15,000 in shares of Best Buy NYSE: BBY on 4/8/2025.
• Sold $1,001 - $15,000 in shares of EOG Resources NYSE: EOG on 4/8/2025.
• Sold $1,001 - $15,000 in shares of CSX NASDAQ: CSX on 4/8/2025.
• Sold $1,001 - $15,000 in shares of Valero Energy NYSE: VLO on 4/8/2025.

Johnson & Johnson Stock Up 0.4 %

Shares of NYSE JNJ opened at $155.90 on Wednesday. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $169.99. The stock's fifty day simple moving average is $159.36 and its two-hundred day simple moving average is $154.77. The stock has a market capitalization of $375.11 billion, a PE ratio of 23.44, a price-to-earnings-growth ratio of 2.56 and a beta of 0.49. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, beating analysts' consensus estimates of $2.59 by $0.18. The company had revenue of $21.89 billion for the quarter, compared to the consensus estimate of $21.65 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. As a group, analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th will be paid a $1.30 dividend. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date of this dividend is Tuesday, May 27th. This represents a $5.20 dividend on an annualized basis and a yield of 3.34%. Johnson & Johnson's payout ratio is 57.84%.

Insider Buying and Selling

In other news, EVP Timothy Schmid sold 403 shares of Johnson & Johnson stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total transaction of $62,928.45. Following the transaction, the executive vice president now owns 15,098 shares in the company, valued at $2,357,552.70. The trade was a 2.60 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Robert J. Decker sold 6,999 shares of the company's stock in a transaction dated Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the completion of the sale, the vice president now directly owns 21,001 shares of the company's stock, valued at $3,483,645.88. This represents a 25.00 % decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several research firms recently commented on JNJ. Wells Fargo & Company reduced their price objective on shares of Johnson & Johnson from $166.00 to $152.00 and set an "equal weight" rating for the company in a research note on Thursday, January 23rd. Raymond James decreased their price objective on Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating for the company in a report on Monday, April 14th. Argus upgraded Johnson & Johnson to a "strong-buy" rating in a research note on Friday, January 24th. Guggenheim reiterated a "neutral" rating on shares of Johnson & Johnson in a research note on Wednesday, April 2nd. Finally, Barclays dropped their price target on Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating on the stock in a research note on Thursday, April 17th. Nine investment analysts have rated the stock with a hold rating, eight have given a buy rating and three have issued a strong buy rating to the company. According to MarketBeat, Johnson & Johnson has an average rating of "Moderate Buy" and an average price target of $171.82.

Institutional Investors Weigh In On Johnson & Johnson

Several hedge funds have recently bought and sold shares of the stock. Principal Financial Group Inc. raised its holdings in Johnson & Johnson by 10.5% in the 3rd quarter. Principal Financial Group Inc. now owns 3,472,312 shares of the company's stock worth $562,723,000 after purchasing an additional 329,473 shares during the period. Invst LLC lifted its position in shares of Johnson & Johnson by 394.0% during the 3rd quarter. Invst LLC now owns 10,290 shares of the company's stock valued at $1,668,000 after buying an additional 8,207 shares in the last quarter. McIlrath & Eck LLC grew its stake in Johnson & Johnson by 10.7% in the 3rd quarter. McIlrath & Eck LLC now owns 2,892 shares of the company's stock valued at $469,000 after acquiring an additional 279 shares during the period. Passumpsic Savings Bank purchased a new stake in Johnson & Johnson in the 3rd quarter worth $262,000. Finally, Te Ahumairangi Investment Management Ltd raised its position in Johnson & Johnson by 10.1% during the third quarter. Te Ahumairangi Investment Management Ltd now owns 50,765 shares of the company's stock worth $8,180,000 after acquiring an additional 4,640 shares during the period. Hedge funds and other institutional investors own 69.55% of the company's stock.

About Representative Bresnahan

Rob Bresnahan Jr. (Republican Party) is a member of the U.S. House, representing Pennsylvania's 8th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Bresnahan (Republican Party) is running for re-election to the U.S. House to represent Pennsylvania's 8th Congressional District. He declared candidacy for the 2026 election. Rob Bresnahan Jr. was born in Kingston, Pennsylvania. He earned a B.S. in business administration, management and operations from the University of Scranton in 2012. His career experience includes working as the chief financial officer and CEO of a family business, an electrical contracting company.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.